LIS Technologies: A $448m Pre-Revenue IPO Test

LIS Technologies: A $448m Pre-Revenue IPO Test

SERRARI GROUP / ANALYST DESK — NASDAQ PROPOSED IPO / URANIUM ENRICHMENT

A laser-enrichment story meets licensing, technical proof, long lead times and a funding requirement larger than proposed IPO proceeds.

$5–$7 — Preliminary IPO range

$18.6m — Gross proceeds at $6 midpoint

$0 — Operating revenue since inception

SERRARI IPO RESEARCH SERIES | RESEARCH CUT-OFF: 09 NOVEMBER 2026

RESEARCH & MARKET EDUCATION • NOT A SECURITIES OFFER OR PERSONAL ADVICE

Executive take: a financing step, not a fuel business

The proposed offer has not priced and the company has not generated operating revenue.

Proposed transaction

A 5 November amended S-1 proposes 3.1m new common shares at $5–$7, implying $18.6m gross proceeds at the $6 midpoint.

Technology thesis

LIS is advancing CRISLA laser-based uranium isotope separation. Demonstration, commercial capacity and regulatory permits remain ahead.

Financial evidence

Nine months to 31 July 2026 produced a $29.69m net loss and $14.82m operating cash outflow. July cash was about $18.8m.

Central assessment

The near-term stock case depends on milestones and financing access; conventional P/E or P/S valuation methods are not meaningful for a no-revenue company.

S-1/A mechanics: what can still change

The preliminary prospectus is not an effective offer, final trading date or final price.

Share count

71.61m existing shares and 3.10m new shares would give 74.71m basic shares after the offer, before over-allotment.

Pricing range

At $5–$7, gross IPO proceeds would be $15.5m–$21.7m, before fees. $18.6m is midpoint arithmetic.

Net cash raised

The issuer estimates roughly $16.6m net at $6 and $19.2m with the 465,000-share over-allotment fully exercised.

Status

The registration statement remains preliminary as of the November 5 amendment; listing and pricing are conditional, not confirmed.

Industrial case: promise and bottlenecks

Commercial nuclear-fuel enrichment is far more complex than laboratory process validation.

CRISLA process

Laser excitation is intended to distinguish isotopic molecules and enable selective separation in controlled conditions.

Demonstration sequence

Prototype, system integration, scaled testing and production engineering must establish repeatable performance before commercial income.

Licensing pathway

A planned enrichment facility requires approvals including from the Nuclear Regulatory Commission; approval is not guaranteed.

Fuel-cycle dependence

UF6 feedstock, conversion, fluorine materials, cylinders and customer offtake all create separate constraints beyond technology readiness.

Losses and liquidity: the scale of the problem

USD millions from the issuer’s preliminary S-1/A; period is nine months ended July 31, 2026.

Metric comparison (periods labeled)

FY25 net loss: 21.54m USD · 9M26 net loss: 29.69m USD · 9M26 operating cash use: 14.82m USD · July 2026 cash: 18.80m USD · Planned 12m cash need: 74.00m USD

Noncomparable periods

FY25 loss covers 12 months; 2026 loss and cash flow cover only nine months ended 31 July.

Funding context

Management estimates $74m of requirements for 12 months to July 2027, substantially above offering net.

Funding gap: proceeds are only a first instalment

Do not treat the IPO cash estimate as sufficient for management’s full development roadmap.

Plan requirements

Management estimates about $74m of cash needs for the 12 months ending 31 July 2027, subject to revision.

Existing cash

Cash was approximately $18.8m at July 31, 2026. This is historical, not a live November cash balance.

IPO contribution

At the midpoint, estimated net IPO proceeds were $16.6m. Actual funds depend on offer completion and costs.

Sensitivity only

$18.8m + $16.6m = $35.4m is less than $74m by roughly $38.6m. This is an illustrative funding comparison, not a forecast.

Use of IPO proceeds: technology dominates

The percentages are management intentions and can be reallocated.

67.5% research and build

Technology R&D, site studies, preparation and experimental testing are the largest intended uses.

12.5% development

Marketing, promotion and business development support future customers and partners.

20% general purposes

Working capital, regulatory compliance, patents and staffing remain necessary as a public registrant.

Capital-market implication

Almost all proceeds are for pre-commercial costs; future funding is likely needed before recurring uranium sales.

Implied equity value: an option on execution

Simple market-cap arithmetic uses 74,711,408 post-issue basic shares; excludes unexercised options.

Illustrative sensitivity / market values

$5 offer: value 373.56m USD · $6 offer: value 448.27m USD · $7 offer: value 522.98m USD

Capitalisation only

74.711m basic shares times $5, $6 or $7; excludes options, warrants and future finance.

No sales multiple

Zero operating revenue makes P/S and P/E inapplicable. These values price a prospective business.

Dilution and ownership: two distinct risks

A small IPO float does not mean the fully diluted cap table is simple.

Basic float proxy

New 3.1m offered shares represent about 4.15% of 74.71m post-issue basic shares, excluding over-allotment.

Warrants and options

The S-1/A details substantial options, including 17.67m shares underlying certain outstanding awards outside the 2023 option plan.

Future issuance

Management expects to raise additional capital; the economic ownership percentage of current shareholders could fall over time.

Trading structure

A small public float can amplify volatility, but post-issue share count is not the same as genuinely freely tradable float.

Transmission channels: nuclear security and funding

Regulatory approval and capital availability are not interchangeable.

Energy security

Domestic enrichment capacity could diversify nuclear-fuel sourcing, but benefits require commercial output and sustained customer demand.

Regulatory scrutiny

Safety, security, environmental licensing and safeguards add cost, time and binary procedural checkpoints.

Supply chain exposure

Enrichment demand depends on reactors, utilities and conversion services; technical development does not guarantee offtake.

Market rates

High interest rates or weak speculative-risk appetite can increase the discount applied to distant uncertain cash flows.

Risk map: pre-commercial and capital intensive

Figure: Risk map — pre-commercial and capital intensive.

Scenario map: four development paths

Revenue timing cannot be determined from the IPO range alone.

Technical progress

Testing and licensing milestones arrive on schedule and future capital can be raised on reasonable terms.

Staged development

Work progresses but additional equity rounds extend timelines and dilute existing owners.

Regulatory delay

Permit, environmental or engineering work postpones plant development and pushes meaningful revenue further out.

Funding interruption

Technology costs outpace accessible finance, forcing scaling delays, cutbacks or strategic restructuring.

Monitoring dashboard: the first five hard milestones

Replace calendar speculation with measurable technical and financial progress.

Offering — Final pricing, SEC effectiveness and first listing date.

Technical proof — Independent validation of process performance.

Licensing — NRC submissions, decisions and facility permits.

Capital needs — Burn rate versus $74m management plan.

Customer traction — Binding offtake and commercial contracts.

Cap table — Option exercises, new rounds and insider holdings.

Market assessment: what the evidence supports

Financial and listing facts are separated from analyst scenarios.

Serrari view: extraordinary upside claims require evidence

The offering offers exposure to a strategically relevant nuclear-fuel technology, not to an established commercial enrichment business. Its valuation hinges on technical proof, regulatory progress and access to substantially more capital than the IPO may raise. Long lead times and potential dilution are central to the investment case.

$448m — Illustrative midpoint basic equity value

$16.6m — Estimated net IPO proceeds at midpoint

$74m — Management’s 12-month cash needs estimate

THE NEXT DECISION POINT

Watch the effective prospectus, actual capital raised, licensing milestones and financing plans; do not mistake early-stage IP for bankable future cash flows.

Sources, methodology and limitations

SERRARI GROUP / ANALYST DESK

Use the linked descriptive phrases below to open the supporting filing, announcement or market record.

L1 — 5 November 2026 SEC amended S-1 prospectus

L2 — SEC filing date and registration status

L3 — SEC prospectus offering and dilution section

L4 — SEC prospectus use of proceeds and capital plan

L5 — SEC prospectus financial statements and risk discussion

L6 — Original October S-1 filing background

METHODOLOGY & COMPARABILITY

Listing was unpriced as of the preliminary S-1/A dated 5 Nov 2026. Equity values are arithmetic post-offer basic market capitalisations at indicative prices, not valuations for investment advice; 74,711,408 basic shares exclude options and over-allotment. Historical cash is from 31 July 2026, while 12-month funding needs are a management planning estimate. A comparison of those figures is not a liquidity forecast.

ANALYST INTERPRETATION & CAUTIONS

All opinions and risk ranks are qualitative analyst judgments rather than probability estimates or financial advice. Figures are as of the stated source dates, not a real-time quote service. Offering terms can change. No recommendation to buy, sell or subscribe to any security is made.

Prepared 09 November 2026 | Serrari Group | Research and market education